Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.
Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis / S. Villani, N. Zanotta, F. Ambrogi, M. Comar, D. Franciotta, M. Dolci, C. Cason, R. Ticozzi, P. Ferrante, S. Delbue. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 310(2017 Sep 15), pp. 91-96.
Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis
S. Villani;F. Ambrogi;M. Dolci;R. Ticozzi;P. Ferrante;S. Delbue
2017
Abstract
Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.File | Dimensione | Formato | |
---|---|---|---|
ms_and_cytokine_preprint.pdf
accesso aperto
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
147.38 kB
Formato
Adobe PDF
|
147.38 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.